A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally in Healthy Male Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs PXS-5382A (Primary)
- Indications Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
- Focus Adverse reactions
- Sponsors Pharmaxis; Synairgen
- 24 Nov 2017 Status changed from planning to recruiting.
- 06 Sep 2017 Planned initiation date changed from 1 Jan 2017 to 1 Oct 2017 as per the Synairgen media release.
- 06 Sep 2017 According to the Synairgen media release, the company will commense phase I trial in Q4 2017.